ENMD 2076 clinical trials
Also written ENMD-2076.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses ENMD 2076 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ENMD-2076
- 8
Studies by the year they started
8 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
CASI Pharmaceuticals, Inc. (6) · University Health Network, Toronto (2)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses ENMD 2076 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar CarcinomaCompletedPhase 2CASI Pharmaceuticals, Inc.NCT02234986Written as ENMD-2076How we know
- Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue SarcomaCompletedPhase 2University Health Network, TorontoNCT01719744Written as ENMD-2076How we know
- Study of ENMD-2076 in Patients With Multiple MyelomaCompletedPhase 1CASI Pharmaceuticals, Inc.NCT00806065Written as ENMD-2076How we know
- A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced CancerCompletedPhase 1CASI Pharmaceuticals, Inc.NCT00658671Written as ENMD-2076How we know
- A Study of ENMD-2076 in Ovarian Clear Cell CancersCompletedPhase 2University Health Network, TorontoNCT01914510Written as ENMD-2076How we know
- Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBCCompletedPhase 2CASI Pharmaceuticals, Inc.NCT01639248Written as ENMD-2076How we know
- Study of Oral ENMD-2076 Administered to Patients With Ovarian CancerCompletedPhase 2CASI Pharmaceuticals, Inc.NCT01104675Written as ENMD-2076How we know
- Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological MalignanciesCompletedPhase 1CASI Pharmaceuticals, Inc.NCT00904787Written as ENMD-2076How we know
Codes
What other systems call ENMD 2076 · ClinicalTrials.gg INT005677
- UNII (FDA) KXQ762CQTHENMD-2076Confirmed FDA, Wikidata
- Wikidata Q27895339enmd-2076Confirmed FDA, Wikidata
- NCI Thesaurus C78190Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KXQ762CQTH | ENMD-2076 | Confirmed FDA, Wikidata |
| Wikidata | Q27895339 | enmd-2076 | Confirmed FDA, Wikidata |
| NCI Thesaurus | C78190 | Aurora A Kinase/Tyrosine Kinase Inhibitor ENMD-2076 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.